Skip to Content

Savella Approval History

  • FDA approved: Yes (First approved January 14th, 2009)
  • Brand name: Savella
  • Generic name: milnacipran
  • Company: Forest Laboratories, Inc. and Cypress Bioscience, Inc.
  • Treatment for: Fibromyalgia

Savella (milnacipran) is a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia.

Development History and FDA Approval Process for Savella

Jan 15, 2009Approval Forest and Cypress Announce FDA Approval of Savella for the Management of Fibromyalgia
Oct 20, 2008FDA Defers Final Action on Milnacipran New Drug Application
Feb 21, 2008Forest and Cypress Announce FDA Acceptance for Review of New Drug Application for Milnacipran for the Treatment of Fibromyalgia
Jan  2, 2008Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.